## The Erythropoietic Effects of Anabolic Steroids.\* (32268)

LORENZO DUARTE, LUIS SÁNCHEZ MEDAL, JUAN LABARDINI, AND LUIS ARRIAGA (Introduced by J. W. Fisher) Instituto Nacional de la Nutrición, Mexico City

Recent clinical observations suggest that certain androgenic steroids with lesser virilizing effects than testosterone are more effective than the latter in the treatment of bone marrow insufficiency. Oxymetholone (1,2), metholone, methenolone and androstanazole(3) have been found capable of inducing a remission in about 50% of adult cases with aplastic anemia, whereas poor results have been obtained with testosterone (4,5). In addition, testosterone has been ineffective in the treatment of congenital pure red cell anemia (Blackfan-Diamond svndrome)(6), a condition in which oxymetholone has been found to be ocassionally useful. Data supporting the suggestion that certain androgenic steroids have greater erythropoietic activity than testosterone are presented here.

*Material and methods*. Three types of experiments were performed in inbred male and female Wistar rats and female Swiss mice.

Experiments A (Table I). Normal female Wistar rats were given 5 mg of iron-dextran intramuscularly, and divided into 4 groups. One group served as controls and received 6 subcutaneous injections of 0.4 ml of sesame oil at weekly intervals; the second, third and fourth groups received 40 mg per week subcutaneously for 6 weeks of testosterone cyclopentylpropionate, metholone propionate or methenolone enanthate, respectively. Two days after the last injection, the red cell mass was measured following intravenous administration of Fe<sup>59</sup> labeled erythrocytes.

Experiments B (Table II). Normal male Wistar rats received daily 5 mg subcutaneous injections of either testosterone propionate, oxymetholone or methenolone acetate daily for 4 days. The mean body weights of the 4 groups of rats employed ranged from 309 to 329 g. Accordingly the average dose was approximately 15 mg per kg. Twenty-four hours after the last injection, they were given I  $\mu$ c Fe<sup>59</sup> intravenoulsy and, 18 hours later, the hematocrit and radioactivity in the red cells were determined on blood obtained by heart puncture. Fe<sup>59</sup> incorporation was estimated assuming a blood volume of 5 ml per 100 g. Animals were kept in a fasting state throughout the experiment.

Experiments C (Table III), Normal female Swiss mice weighing 19 to 24 g were placed on a protein-free diet for 10 days. On days 2 and 3, the animals received subcutaneous injections of 2.5 mg of either testosterone propionate, oxymetholone in aqueous solution, metholone in aqueous or in oil solution, or methenolone acetate. On day 7, 1  $\mu$ c of Fe<sup>59</sup> was given intraperitoneally; on day 10 blood was removed by heart puncture and the hematocrit (micro) and radioactivity present in the red cells were determined. The blood volume was assumed to be 5 ml/100 g. The protein free diet used was prepared in our laboratory and consisted of the following ingredients:

	70
Starch	69.1
Dextrose	17.6
Cellulose	4.0
Corn oil	5.0
Salt mixture(7)	4.0
Vitamin mixture	0.3

M

Results and discussion. The results of the present study, shown in Tables I to III, confirm that low virilizing hormones, such as metholone, methenolone and oxymetholone, stimulate erythropoiesis. They are capable of inducing a polycythemic response in the normal animal (Table I) and of increasing  $Fe^{59}$  incorporation in red cells of rats and mice in which erythropoiesis had been depressed by fasting and protein-free feeding respectively (Tables II and III). The erythropoietic effect

<sup>\*</sup> The generous supply of iron dextran (Imferon) by Farmaceuticos Lakeside, S. A.; of methenolone (Primobolan) by Schering, A. G.; of Metholone (Trolban) and Oxymetholone (Anadrol) by Syntex; and of testosterone cyclopentylpropionate (T.C.P.) by the Upjohn Co. is gratefully acknowledged.

	No of	Mean w	veights		RCM	Increase RCM
Drug	animals	Initial	Final	Ht (%)	(ml/100 g)	(%)
Controls	15	230	271	43.8	$2.586 \pm .065$	-
Testosterone	14	274	289	48.4	$2.889 \pm .070$	11.7
Methenolone enanthate	14	252	301	48.1	$2.941 \pm .062$	13.7
Metholone	11	268	296	49.6	$3.234 \pm .210$	25.0
+ Standard error						

 TABLE I. The Effects of Testosterone and Other Anabolic Hormones on Hematocrit and Total

 Circulating Red Cell Mass in Normal Female Rats.

Analysis of variance by Duncan's 1	F test modified	by Kramer(12)	
	Significant at		
Groups	.05 level	.01 level	
Controls vs testosterone	yes	no	
Controls vs methenolone	yes	no	
Controls vs metholone	yes	yes	
Testosterone vs methenolone	no	no	
Testosterone vs metholone	yes	no	
Methenolone vs metholone	no	no	

is seen in both female and male animals and, in all experiments, the results in the animals injected with the anabolics differed significantly from the controls.

The results also support our hypothesis that some anabolic hormones have a higher erythropoietic activity than testosterone. Response to testosterone was constantly smaller than that to anabolics given at equal doses: a greater increase in red cell mass and/or in incorporation of iron was always obtained with oxymetholone and metholone; methe-

TABLE II. Influence of Testosterone and Anabolic Hormones on Fe<sup>50</sup> Incorporation in RBC of Fasted Rats.

Drug	No. of animals	Fe <sup>59</sup> (%)	Increase in % over control
Controls	8	$4.20 \pm .17$	
Testosterone propionate	7	$5.64 \pm .29$	34
Methenolone acetate	7	$5.20 \pm .48$	23
Oxymetholone	7	$8.62 \pm .61$	105
$\pm$ Standard e	rror		

Analysis of variance by Duncan's F test modified by Kramer(12)

	Significant at		
Group	.05 level	.01 level	
Controls vs testosterone	yes	yes	
Controls vs methenolone	yes	no	
Controls vs oxymetholone	yes	yes	
Testosterone vs methenolone	no	no	
Testosterone vs oxymetholone	yes	yes	
Methenolone vs oxymetholone	yes	yes	

TAB	LE I	II. In	fluence	e of	Testos	terone	and	Ana-
bolic	Horr	nones	on Fe	<sup>59</sup> Ir	icorpora	tion i	in RE	SC of
$\mathbf{F}$	emale	Swiss	Mice	$\mathbf{on}$	a Prote	in-Fre	e Die	et.

- -

Drug	No. of animals	Fe <sup>59</sup> (%)	Increase in times con- trol value
Controls	23	$.178 \pm .023$	
Testosterone propionate	7	$2.999 \pm 1.264$	16.8
Oxymetholone (aqueous)	7	$4.065 \pm 2.046$	22.8
Metholone (oil)	7	$5.057 \pm 1.399$	28.4
Methenolone acetate	13	$5.747 \pm .846$	32.2
Metholone (aqueous)	14	$6.907 \pm 1.535$	38.8
+ Standard e	rror		

Analysis of variance by Duncan's F test modified by Kramer(12)

	Signif	icant at	
Group	.05 level	.01 level	
Controls vs testosterone	no	no	
Controls vs oxymetholone	yes	no	
Controls vs metholone (oil)	yes	yes	
Controls vs methenolone	yes	yes	
Controls vs metholone (aq.)	yes	yes	
Testosterone vs metholone (aq.)	yes	no	

All other group differences were non-significant.

nolone, the only drug tested in the 3 types of experiments, failed to show its supremacy over testosterone only in the one using male animals (Table II). In some experiments oxymetholone (Table II) and metholone (Tables I and III) had an effect significantly greater than that of testosterone. Two isolated observations are in agreement with our point of view of a greater erythropoietic activity of anabolics as compared with testosterone. Gurney and Fried(8) observed a moderately greater  $Fe^{59}$  incorporation with nandrolone than with testosterone in mice, and Meineke and Crafts(9) reported that norethandrolone but not testosterone stimulates the  $Fe^{59}$  incorporation in hypophysectomized rats.

On the basis of these studies it is apparent that some androgenic steroids have more erythropoietic activity than testosterone. Our data also suggest that the erythropoietic effect of androgens may be a third type of activity of these steroids, independent of their virilizing and myotrophic activities. This possibility is suggested by the observation that compounds having less than one fourth of the virilizing effect of testosterone, like methenolone(10), are more active erythropoietically than testosterone. On the other hand, metholone which has lesser anabolic effect than testosterone, oxymetholone and methenolone (10,11) appears to be the more potent erythropoietic agent of all the 4 steroids tested.

Summary. The erythropoietic effects of testosterone, oxymetholone, methenolone and metholone were compared in normal and fasted rats as well as mice on a protein free diet. The results of these androgenic-anabolic steroid studies are as follows: 1) methenolone and metholone produced a more marked erythropoietic response than testosterone when tested in normal female rats; 2)  $Fe^{59}$  incorporation in RBC of male fasted rats was higher with oxymetholone than with testos-

terone; and 3) testosterone was markedly less effective than oxymetholone, methenolone and metholone in increasing  $Fe^{59}$  incorporation in RBC of mice on a protein free diet. These results suggest that the erythropoietic activities of the above steroids are independent of their virilizing and anabolic effects, since testosterone is the most virilizing of the four agents and metholone, which induced the greatest erythropoietic effects, has the least anabolic action.

1. Sánchez-Medal, L., Pizzuto, J., Torre-López, E. Derbez, R., Arch. Intern. Med., 1964, v113, 721.

2. Romero-García, F., Rosales, J. J., Sangre., 1965, v10, 365.

3. Caviles, A. P., Arcinue, E., Castillo, G. B., Buenaventura, A., Act. Med. Philippina., 1965, v1, 137.

4. Seligman, M., Nouv. Rev. Franc. d'Hem., 1966, v6, 408.

5. Bernard, J., Najean, Y., Series haematologica 5. Munksgaard, Copenhagen, 1965, v5, 1.

6. Diamond, L. K., Magill, F. B., Am. J. Dis. Child., 1961, v102, 403.

7. Hegsted, D. M., Mills, R. C., Elvehjem, C. A., Hart, E. B., J. Biol. Chem., 1941, v133, 459.

8. Gurney, C. W., Fried, W., J. Lab. Clin. Med., 1965, v65, 775.

9. Meineke, H. A., Crafts, R. C., Conference on Erythropoietin, N. Y. Acad. Sci. June, 1966.

10. Suchowsky, G. K., Junkmann, K., Acta Endocrinol., 1962, v39, 68.

11. Dorfman, R. I., Dorfman, A. S., ibid., 1963, v42, 245.

12. Steel, R. G. D., Torrie, J. H., Principles and Procedures of Statistics, McGraw-Hill, New York, 1960, p99.

Received January 10, 1967. P.S.E.B.M., 1967, v125.

## Juxtaglomerular Cells in CCl<sub>4</sub>-Treated Experimental Hypertension.\* (32269)

HUBERT F. LOYKE AND JOHN S. MACKRELL (Introduced by Matthew N. Levy) Department of Clinical Investigation, Research Division, St. Vincent Charity Hospital Cleveland, Ohio

Renal and endocrine (DCA) hypertensive rats have been rendered normotensive by  $CCl_4$  injections (1,2). The possibility that alterations in renin secretion were taking \* This study was supported by USPHS Grant H-4107.